ArticleCureus2026
Trends in Chronic Myeloid Leukemia Mortality by Race, Age, and Gender in the United States Between 1999 and 2020.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Chronic myeloid leukemia (CML) represents a significant portion of leukemia cases annually in the United States. Despite advances in treatment, disparities in CML mortality persist across different demographic groups, particularly by race, age, sex, and social determinants of health. This study explores mortality trends by race, age, and gender in CML from 1999 to 2020 in the United States. Methods Mortality data for CML (ICD-10 code C92.1) were analyzed from the CDC Wonder Database (1999-2020). Age-adjusted mortality rates (AAMRs) were calculated per 100,000 persons and stratified by sex, race (White and African American), and adult age groups. Results While overall CML mortality rates declined after the introduction of tyrosine kinase inhibitors (TKIs) in 2001, disparities persist. Older adults, males, and African Americans exhibit higher mortality rates compared to their counterparts. African Americans' AAMR decreased from 0.7 in 1999 to 0.35 by 2008 (annual percent change (APC) of -8.5%, p < 0.01). White Americans had a larger reduction in AAMR, from 0.65 in 1999 to 0.3 by 2007 (APC of -10.0%, p < 0.01). Age-specific analyses highlighted a decrease in mortality across adult age groups. The oldest group, aged ≥85 years, had an AAMR of 5.25 in 1999, which decreased to 4.7 by 2020 but remained significantly higher than other age groups. Conclusions Despite the effectiveness of TKIs, significant disparities in CML mortality remain, particularly among older adults, males, and African Americans. Addressing these disparities requires a multifaceted approach, including better access to care, increased representation in clinical trials, and tailored interventions for each demographic group, which is critical to reducing these disparities and improving outcomes for all patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.